Emtricitabine/tenofovir disoproxil fumarate

Drug Profile

Emtricitabine/tenofovir disoproxil fumarate

Alternative Names: Emtriva®/Viread®; F/TDF; FTC/TDF; TDF/FTC; Tenofovir disoproxil fumarate/emtricitabine; Truvada; TVD; Viread®/Emtriva®

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gador; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; Stendhal Mexico; University of Alberta; University of Washington
  • Class Antiretrovirals; Deoxyribonucleosides; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase III Hepatitis B
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 14 Mar 2017 International Partnership for Microbicides and Gilead Sciences plan the REACH phase II trial for HIV infection (Prevention, In volunteers, Combination therapy) in South Africa (NCT03074786)
  • 27 Feb 2017 Gilead Sciences has patent protection for emtricitabine/tenofovir disoproxil fumarate in USA and European Union (Gilead Sciences 10-K, February 2017)
  • 23 Feb 2017 CHMP recommends approval of label extension of emtricitabine/tenofovir disoproxil fumarate for HIV infections (In adolescents, Second-line therapy or greater) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top